Joseph C. Papa - 03 Mar 2026 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
President and CEO, Director
Signature
/s/ Richard S. Lindahl, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
03 Mar 2026
Net transactions value
$0
Form type
4
Filing time
05 Mar 2026, 21:40:29 UTC
Previous filing
15 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PAPA JOSEPH C President and CEO, Director 300 PROFESSIONAL DRIVE, GAITHERSBURG /s/ Richard S. Lindahl, Attorney-in-fact 05 Mar 2026 0001242215

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Tax liability -37,055 -11% $8.44* 305,445 05 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EBS Employee Stock Option (Right to buy) Award +252,194 +16% $0.000000* 1,784,694 03 Mar 2026 Common Stock 252,194 $8.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of performance stock units.
F2 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.